RE: PALOH study/AIHL test gaining wordlwide visibility18 Jun 2021 17:43
Hi all, Have been following this board, thought i would join the chat, usually i just stick to twitter!
Anyway look forward to some updates from thr company soon. I know alot of you have waited for a lot longer. Some thoughts from myself :
1. Fda approvals can take time especially during current times, they are overloaded with applications. Saying that, I do find it odd that they haven't approved an eua for over an year!
2. GDR are a small player in a very very competitive market, but for me having Danaher partnership is key for them to be successful.
3. Company doesn't have alot of cash so that's obviously a risk (dillution from offerings etc), but they may go down the debt financing route as its cheaper.
4. I feel disease diagnostic industry will only grow even post covid, so if GDR can truly have a market leading product, it can go a long way.
5. Ultimately, it will be all about the sales amd revenue! So look forward to news on that front.
6. Why it caught my eye now is,
>sub 40m mcap,
>with partnership with bn$ company,
>ce markings and approvals in several countries
> a product which had near 100% effectiveness
>multiple pipelines (ie not just relying on covid)
Let's see how the next few months play out here.